Belkyra is the first non-surgical treatment for unwanted fullness in the chin area with the FDA certificate that proofs it’s high quality and safety.
The double chin is an aesthetic defect, closely related to the excess of adipose tissue under the chin. We shouldn’t call it an illness, but in many people it can cause serious mental discomfort: 73% of people admit that their chin is a problem for them*. The same number of people complain about lines and wrinkles around the eyes, however, double chin treatment is much less popular. Meanwhile, the chin line strongly influences the assessment of the person’s age, therefore taking care of our appearance we should never forget about this important detail.
Submental fullness, also known as a “double chin”, can occur as a result of aging, genetics or weight gain. To get rid of the defect, you no longer have to undergo surgical procedures – the pharmaceutical company Allergan has resolved the problem by developing BELKYRA formulation that permanently destroys fat cells under the chin, resulting in contour improvement.
How it works?
BELKYRA permanently destroys adipose tissue by an active ingredient known as deoxycholic acid- a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected under the chin Belkyra destroys fat cells resulting in a noticeable reduction in fullness. Clinical studies have shown that the formulation contributes to the increased amount of collagen around its application. Prior to administration of Belkyra, the doctor examines the chin area to exclude other potential causes of chin convexity (like abnormal thyroid function or lymph nodes). The treatment is repeated once a month until achieving a satisfactory result (up to 6 treatments). .
*The study was conducted among respondents interested in aesthetic treatments by Allergan